August 25, 2025 — Leads & Copy — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) has received a $2,054,651 research grant from the National Cancer Institute to advance Bria-PROS+, a personalized immunotherapy for prostate cancer. The grant will fund manufacturing and a Phase 1/2a study in patients with advanced prostate cancer.
Dr. William Oh of Yale Cancer Center is the Principal Investigator for the study.
BriaCell’s President and CEO, Dr. William V. Williams, noted the grant will expedite clinical development and validates their immunotherapy approach.
BriaCell’s Chief Scientific Officer, Dr. Miguel Lopez-Lago, believes the Bria-OTS+ platform will advance personalized cancer care by overcoming the complexities, costs and delays of traditional treatments.
William V. Williams, MD, President & CEO, 1-888-485-6340, info@briacell.com
Source: BriaCell Therapeutics Corp.
